"Designing Growth Strategies is in our DNA"

Connected Drug Delivery Devices Market Size, Share & Industry Analysis, By Type (Injectable Devices and Inhalation Devices & Others) By Technology (Bluetooth, NFC, and Others) By End User (Homecare Settings and Hospitals) and Regional Forecast, 2019-2026

Region : Global | Published Date: Nov, 2019 | Report ID: FBI100380| Status : Published

 

KEY INDUSTRY INSIGHTS

Play Audio Listen to this report overview

The global connected drug delivery devices market size was USD 361.1 million in 2018 and is projected to reach USD 4,062.7 million by 2026, exhibiting a CAGR of 35.4% during the forecast period.


Connected drug delivery devices are unified with capabilities that include connectivity to a wide range of digital services. These devices are being developed by various market players with an aim to support superior patient supervision and counselling. Connected drug delivery devices include many features, such as adherence trackers, dosing remainders, and patient diaries to collect health information as well as tools for patient education. These devices are prominently used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), diabetes, and other cardiovascular disorders.


Increasing adoption of electronic technology in healthcare devices coupled with the efficiency of drug delivery devices in treatment procedures are projected to drive the connected drug delivery devices market growth during the forecast period. Combined with this, an increasing prevalence of asthma, COPD, and diabetes is anticipated to offer lucrative opportunity for the increased adoption of connected drug delivery devices during the forecast period. For instance, according to a study conducted by the Centers for Disease Control and Prevention (CDC), in 2016, an estimated 26.5 million people in the U.S. were suffering from asthma.


Get comprehensive study about this report by, request a free sample copy


Furthermore, certain factors, such as increasing healthcare expenditure, rising disposable incomes, increasing awareness of connected devices in developing nations is projected to fuel the connected drug delivery devices market growth by 2026.


MARKET DRIVERS


“Increasing Prevalence of Chronic Diseases to Propel Growth of Market”


The increasing prevalence of chronic diseases, such as asthma, COPD, and diabetes across the globe is creating substantial amount of opportunities for the growth of the connected drug delivery devices market. For instance, according to a study conducted by the Global Burden of Disease, in 2015, the prevalence of COPD grew by an estimated 14.7% during 1990-2015. Additionally, there is a gradual shift of preference from manual drug delivery devices to the connected drug delivery devices owing to their possession of superior benefits.


Rising emphasis on preventive care is one of the prominent factors anticipated to boost the adoption of connected drug delivery devices during the forecast period. The Lancet Respiratory Medicine, for instance, had published a study in 2015. It reported that the adoption of smart inhalers amongst asthmatic children in New Zealand grew up to 84.0% during 2014-2015.


“Superior Procedural Outcomes of Connected Drug Delivery Devices to Augment Growth”


Connected drug delivery devices can be connected with smartphones with the help of Near Field Communications (NFC) and Bluetooth, enabling dose monitoring and dosing remainder mechanisms. Additionally, these devices offer patient education tools which minimizes the errors in dosing procedures, resulting into reduction in hospitalization and treatment costs. For instance, a study conducted by Propeller Health, one of the prominent players in connected drug delivery devices states that, in 2016, patients who used sensor connected inhalers witnessed an estimated 60.0% reductions in the hospital visits during the course of the study. Additionally, extensively increasing research and development activities are projected to offer more facilities to the patients, which will eventually drive the connected drug delivery devices market by 2026.


SEGMENTATION


By Type Analysis


“Injectable Devices Segment to Dominate Stoked by Possession of Numerous Benefits”


In terms of type, the market is categorized into injectable devices and inhalation devices & others. The injectable devices segment is estimated to account for the maximum portion of the market. Certain factors, such as the numerous benefits offered by smart injectable devices over the traditional injectable devices and an increasing prevalence of chronic conditions, namely, cancer, neural disorders, diabetes, and others are actively contributing in the growth of the injectable devices segment. Moreover, entry of many drug manufacturers to develop smart injectable devices is projected to offer significant growth opportunities for the injectable devices segment during the forecast period.  


To get details on market share, speak to our analyst


The inhalation devices & others segment, on the other hand, is expected to propel owing to the growing prevalence of asthma, chronic obstructive pulmonary disorders (COPD), and other respiratory diseases. Also, the rising emphasis on the utilization of digital devices for better treatment outcomes would accelerate growth. Moreover, increasing collaborations between the market players and healthcare institutions is further expected to expand the inhalation devices segment in the global connected drug delivery devices market during the forecast period.


By Technology Analysis


“Higher Usability and Compatibility in Connected Drug Delivery Devices Expected to Boost Bluetooth Segment”


On the basis of technology, the market can be segmented into Bluetooth, near field communication (NFC), and others. In terms of revenue, the Bluetooth segment is estimated to dominate the market owing to the higher utilization of the technology in order to connect drug delivery devices to smartphones. Moreover, higher compatibility of Bluetooth technology with other drug delivery devices and ease of use is expected to drive the Bluetooth segment over the forecast period. Furthermore, numerous benefits offered by the NFC devices, such as extended battery life and superior data transmission are projected to increase the adoption of these devices, which will eventually drive the growth of the NFC segment by 2026.


By End User Analysis


“Homecare Setting Segment to Lead: Increasing Adoption of Connected Drug Delivery Devices Will Favor Growth”


On the basis of end user, the market is segmented into homecare settings and hospitals. The homecare settings segment is estimated to dominate the market throughout the forecast period. An increasing adoption of the connected drug delivery devices owing to a need to provide better patient experience, coupled with a rise in the prevalence of COPD and asthma are projected to offer substantial amount of growth for this segment in the  connected drug delivery devices market.


Besides, the rapidly developing healthcare infrastructure and rising emphasis on the utilization of improved procedural outcomes are anticipated to offer growth opportunities to the hospital segment in the connected drug delivery devices market during the forecast period.


REGIONAL ANALYSIS


North America generated a revenue of USD 253.0 million in 2018 and is projected to dominate the global connected drug delivery devices market throughout the forecast period. Highly developed healthcare infrastructure and healthcare spending, presence of significant market players, and strategic collaborations are the major factors attributable to the dominance of this region in the market. Combined with this, an increasing prevalence of chronic diseases in the U.S. and rising focus on preventive care are anticipated to drive growth of this region during the forecast period.


In Europe, the increasing adoption of connected drug delivery devices and growing demand for digital medical devices in Germany, UK, & France, owing to a need to enhance the patient experience are attributable to the growth of connected drug delivery devices market in this region.


North America Connected Drug Delivery Devices Market Size, 2018

To get geographical overview of this market, request a free sample copy


In Asia Pacific, increasing awareness about connected drug delivery devices, cost benefits, and rapid adoption of medical technology in China, India, etc. are generating huge opportunities for the growth of the market. In the rest of the world, implementation of intense marketing strategies by market players, increasing healthcare spending, and expected expansion of the distribution network of key players are some of the primary factors augmenting the connected drug delivery devices market.


INDUSTRY KEY PLAYERS


“Adherium, Propeller Health, and Others to Hold Considerable Market Share”


The global market is a highly fragmented market as a large number of players operate actively here. Adherium, Propeller Health (A ResMed Company), and Cohero Health Inc. are expected to lead the smart inhalers market. Certain factors, such as ownership of technology, emphasis on research & development activities, and robust focus on the consolidation of sales channels are attributable for the companies to hold major connected drug delivery devices market share. Also, players, namely, Roche, F. Hoffmann-La Roche Ltd., West Pharmaceutical Services, and others are actively contributing in the connected injectable devices segment owing to their well-established marketing channels and strong brand presence.


List Of Key Companies Profiled:



  • Proteus Digital Health

  • Ypsomed Holding

  • F. Hoffmann-La Roche Ltd

  • BD

  • West Pharmaceutical Services

  • Propeller Health (A ResMed Company)

  • Adherium

  • Cohero Health, Inc.


REPORT COVERAGE


The report provides detailed information regarding various insights of the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and other related challenges. It further offers an analytical depiction of the connected drug delivery devices market trends and estimations to illustrate the forthcoming investment pockets. It is quantitatively analyzed from 2019 to 2026 to provide the financial competency of the market. The information gathered in the report has been taken from several primary and secondary sources.


To get information on various segments, share your queries with us


Along with this, the report provides an elaborative analysis of the global market dynamics and competitive landscape. Various key insights presented in the report are the technological advancements in connected drug delivery devices market, new product launches by key players, key industry developments: mergers, acquisitions & partnerships, regulatory scenarios, and trends of usage of connected drug delivery devices.


REPORT SCOPE & SEGMENTATION











































 ATTRIBUTE



 DETAILS



Study Period



  2015-2026



Base Year



  2018



Forecast Period



  2019-2026



Historical Period



  2015-2017



Unit



  Value (USD million)



Segmentation



By Type



  • Injectable Devices

  • Inhalation Devices and Others



By Technology



  • Bluetooth

  • NFC (Near Field Communication)

  • Others



By End User



  • Homecare Settings

  • Hospitals



By Region



  • North America

  • Europe

  • Asia Pacific

  • Rest of the World



 


INDUSTRY DEVELOPMENT:



  • In October 2019, Phillips-Medisize - a Molex Company, announced the projected launch of its first electronic-enabled drug delivery device. According to the announcement, the company is expected to launch its product in the second half of 2020.

  • January 2019, FindAir, a European company launched their smart inhaler, FinadAir ONE in the Europe market. The device is intended to offer treatment for patients suffering from COPD and asthma.

  • December 2018, Teva Pharmaceutical received FDA approval for its smart inhaler. The device is capable of recording and maintaining dosage information.  


Frequently Asked Questions

Fortune Business Insights says that the connected drug delivery devices market is projected to reach USD 4,062.7 million by 2026.

The value of the North America connected drug delivery devices market was USD 253.0 million in 2018.

The connected drug delivery devices market is projected to grow at a CAGR of 35.4% during the forecast period (2019-2026).

The injectable devices segment is the leading segment in the connected drug delivery devices market.

An increasing prevalence of chronic conditions, such as COPD, asthma, and diabetes coupled with a rising adoption of connected drug delivery devices are the key factors driving the connected drug delivery devices market.

Adherium, Propeller Health (A ResMed Company), and West Pharmaceutical Services are the major players in the connected drug delivery Devices market.

North America is expected to hold the highest market share in the connected drug delivery devices market.

Increasing prevalence of respiratory diseases and better patient experience are the factors that are expected to drive the adoption of connected drug delivery devices.

A gradual shift from traditional drug delivery devices to the connected drug delivery devices is the key trend of the connected drug delivery devices market.

Connected Drug Delivery Devices Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2015-2017
  • 135

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X